Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “anti-”

1,068 pharma patents match "anti-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,068
Index total 30,257
Page 12 / 45

Quick answer

This filtered view shows 1,068 pharmaceutical patents matching "anti-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,068 results for “anti-” · 30,257 patents in full index Clear search

  1. US 11649273

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  2. US 11648318

    Anti-transferrin receptor (TFR) antibody and uses thereof

    Dyne Therapeutics, Inc. · Granted May 16, 2023 · Expires May 11, 2043

    granted
  3. US 11648307

    Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

    The Board of Regents of the University of Texas System · Granted May 16, 2023 · Expires May 11, 2043

    granted
  4. US 11642390

    Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 9, 2023 · Expires May 4, 2043

    granted
  5. US 11633501

    Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  6. US 11629195

    Anti-IL2 receptor gamma antigen-binding proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  7. US 11623010

    Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition and methods for treatment

    BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD. · Granted Apr 11, 2023 · Expires Apr 6, 2043

    granted
  8. US 11618784

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted
  9. US 11608380

    Anti-EGFRvIII antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 21, 2023 · Expires Mar 16, 2043

    granted
  10. US 11603413

    Anti-TMPRSS2 antibodies and antigen-binding fragments

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2023 · Expires Mar 9, 2043

    granted
  11. US 11596690

    Stabilized formulations containing anti-IL-33 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  12. US 11596688

    Predicting outcome of treatment with an anti-α4β7 integrin antibody

    Takeda Pharmaceutical Company Limited · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  13. US 11596696

    Combination therapy with an anti-CD25 antibody-drug conjugate

    ADC THERAPEUTICS SA · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  14. US 11578127

    Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  15. US 2023040008

    ANTI-HER2 POLYPEPTIDES DERIVATIVES AS NEW DIAGNOSTIC MOLECULAR PROBES

    BRACCO IMAGING SPA [IT] · Granted Feb 9, 2023 · Expires Feb 4, 2043

    granted
  16. US 11572372

    Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds

    Medshine Discovery Inc. · Granted Feb 7, 2023 · Expires Feb 2, 2043

    granted
  17. US 11564937

    Nucleoporins as drug targets for anti-proliferative therapeutics

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  18. US 11566076

    Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

    Five Prime Therapeutics, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  19. US 11559576

    Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  20. US 11559583

    Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

    Five Prime Therapeutics, Inc. · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  21. US 11548947

    Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  22. US 11548940

    Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Rani Therapeutics, LLC · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  23. US 11548932

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted
  24. US 11541070

    Administration of an anti-activin-A compound to a subject

    Atara Biotherapeutics, Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted